Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Neuroprotective and Cardioprotective Effects Of Palm Vitamin E Tocotrienols

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by University of Science Malaysia.
Recruitment status was  Active, not recruiting
Malaysia Palm Oil Board
Information provided by (Responsible Party):
Yuen Kah Hay, University of Science Malaysia Identifier:
First received: September 15, 2008
Last updated: July 10, 2012
Last verified: July 2012

The purpose of the study is to assess the neuroprotective, anti atherogenic and hepatoprotective properties of tocotrienols (palm vitamin E) supplementation as determined by white matter lesion load on serial magnetic resonance imaging (MRI), carotid artery magnetic resonance angiography (MRA) and liver ultrasound (US) as well as lipid profile analysis.

Condition Intervention Phase
Cerebrovascular Disorders
Dietary Supplement: Palm vitamin E (tocotrienol) or placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E)

Resource links provided by NLM:

Further study details as provided by University of Science Malaysia:

Primary Outcome Measures:
  • Regression of white matter lesion load in terms of numbers and size in the brain [ Time Frame: 1 to 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Regression of the carotid artery stenoses in terms of percentage [ Time Frame: 1 to 2 years ] [ Designated as safety issue: No ]
  • The improvement in the lipid profile other markers associated with increased cardiovascular risk [ Time Frame: 1 to 2 years ] [ Designated as safety issue: No ]
  • Improvement in liver echogenicity. [ Time Frame: 1 to 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: January 2008
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: MRI(+ve), MRI(-ve)
Volunteers in MRI(+ve) group will be randomized into two groups to receive either palm vitamin E (tocotrienol)or placebo. The same goes to the volunteers in the MRI(-ve) group as well.
Dietary Supplement: Palm vitamin E (tocotrienol) or placebo
200 mg softgel tocotrienol or placebo to be taken orally twice a day.
Other Name: Tocovid 200mg
Placebo Comparator: Tocotrienol
Dietary Supplement: Palm vitamin E (tocotrienol) or placebo
200 mg softgel tocotrienol or placebo to be taken orally twice a day.
Other Name: Tocovid 200mg

Detailed Description:

Stroke is the third largest cause of death after heart disease and cancer in Malaysia. It is estimated that 52,000 Malaysians suffer stroke annually. In 2005, 3245 cases of stroke were fatal. It is projected that the number of fatal stoke cases will exceed 25,000 in 2020.

It was found that at nanomolar concentrations, α-tocotrienol but not α-tocopherol prevent glutamate-induced neuron cell death in mice through inhibition of c-Src kinase and 12-lipoxygenase. Tocotrienol-supplemented rats showed more protection against stroke-induced injury compared with matched controls.

White matter lesion as detected on magnetic resonance imaging (MRI) is closely related to vascular events of the brain. MRI and histopathological study has shown that the larger white matter lesions not usually conforming to usual areas infarcts can actually represent areas of subclinical infarct. In addition there is positive correlation between white matter lesions with established vascular risk factors.

The Rotterdam Scan Study showed that elderly people with silent brain infarcts and white matter lesions are at a strongly increased risk of clinical stroke, which could not be explained by the major stroke risk factors alone.

Several recent studies showed that white matter lesions may be an independent prognostic measure of future stroke risk.

White matter hyperintensities as detected on MRI is closely related to vascular events of the brain and in some instances represent subclinical infarcts.

It is therefore conceivable to study the neuroprotective properties of tocotrienol supplementation in humans by looking at serial changes of white matter disease load.

Tocotrienol supplementation brings about various favourable effects including improving lipid profiles, lowering of thromboxane B2 and platelet factor 4 and reduced LDL oxidation. Carotid artery MR angiography is an established and robust technique in the evaluation of carotid artery stenosis. Therefore, to study the anti-atherogenic effects of tocotrienols supplementation, serial MR angiography of the carotid arteries are done.

Non-alcoholic fatty liver disease (NAFLD) is emerging as a not fully understood, both in aetiology and significance, liver disorder. FLD is reported to be the most common cause of chronic liver disease in the U.S.A. and other western countries with a prevalence rate ranging between 15% to 30% of the adult population. However, limited data are available for Malaysia.

US imaging provides valuable information of the liver condition with a sensitivity of 93-100%. Frequently NAFLD is associated with dyslipidemia, obesity, insulin resistance and type II diabetes and it represents the liver component of the metabolic syndrome (MetS). Patients with NAFLD are reported to have low levels of serum vitamin E. NAFLD patients present a significant increase in cardiovascular (CV) risk, thus linking NAFLD, MetS and accelerated atherosclerosis.


Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Participant able to understand and has signed and dated the Informed Consent Form
  • Participant can be either a male or female
  • Participant is more than 35 years of age
  • Participant has total cholesterol between 5.2 - 6.2 mmol/L and LDL cholesterol between 2.6 - 4.2 mmol/L
  • Participant is able to comply with visits and medications
  • Participant has normal liver function (total protein, total albumin, total globulin, total bilirubin, SGOT and SGPT)

Participants who satisfy the Inclusion and Exclusion Criteria for Study in General with one or more of the following conditions will be eligible for MRI screening:

  • More than 40 years of age
  • Stable hypertension requiring only out-patient management
  • Diabetes mellitus requiring only out-patient management
  • Ischaemic heart disease requiring only out-patient management
  • Body mass index more than 25 (overweight or obese)

Exclusion Criteria:

  • Female participants who are pregnant
  • Participant has previously received vitamin E supplementation (tocotrienols or tocopherols) within the past 3 months at the time of recruitment
  • Participant has a history of cancer or has undergone radiation therapy
  • Participant has a history of major organ dysfunction, such as moderate or severe hepatic impairment, severe renal insufficiency, severe or unstable cardiovascular, respiratory, hematological, endocrinological, neurological or other somatic disorders resulting in previous hospitalization.
  • Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.
  • Participant is requiring long term anti-epileptics, hypnotics, and chronic medications for hypercholesterolemia
  • Participant has very high cholesterol levels, total cholesterol above 6.2 mmol/L and LDL cholesterol above 4.2 mmol/L, which require medical treatment.
  • Participant is requiring long term non-steroidal anti-inflammatory (NSAID) medication.
  • Participant has a history of hypersensitivity to vitamin E.
  • Participant has signs of alcohol and drug dependence or abuse.
  • Participant is unable to understand and comply with the elements in the consent form.

In addition, the participant must not have any contraindication to have MRI examinations including:

  • Biostimulators (e.g. cardiac pacemaker and implanted spinal cord stimulator)
  • Neurostimulators
  • Aneurysm clips in the brain
  • Cochlear implants
  • Hearing aids
  • Orthopaedic implants less than 2 months old
  • Metal fragments in eyes Any further implants or foreign body not listed above should have the safety assessed by a radiologist prior to recruitment into the MRI study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00753532

Kepala Batas Hospital
Kepala Batas, Penang, Malaysia, 13200
Sponsors and Collaborators
University of Science Malaysia
Malaysia Palm Oil Board
Principal Investigator: Yuen Kah Hay, Phd University of Science Malaysia
  More Information

No publications provided by University of Science Malaysia

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yuen Kah Hay, Professor, University of Science Malaysia Identifier: NCT00753532     History of Changes
Other Study ID Numbers: MPOB-USM-Version 1.4
Study First Received: September 15, 2008
Last Updated: July 10, 2012
Health Authority: Malaysia: Ministry of Health

Keywords provided by University of Science Malaysia:
Carotid artery stenoses
Brain ischaemia
Lipid abnormalities
Fatty Liver

Additional relevant MeSH terms:
Cerebrovascular Disorders
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Vitamin E
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents processed this record on November 20, 2014